Nutriband Inc. CEO Temporarily Steps Down to Pursue Irish Presidential Candidacy

Nutriband Inc. (NASDAQ: NTRB) has announced a significant temporary leadership change as CEO Gareth Sheridan steps aside for three months to pursue his candidacy in the upcoming Irish Presidential election. This period will cover the critical phases of nomination hearings and voting scheduled for September and October. During Sheridan's absence, Co-Founder and Chairman Serguei Melnik, whose expertise spans over 20 years in capital markets and corporate strategy, will assume the role of interim CEO. This transition is poised to ensure the company remains on track toward its ambitious 2026 NDA filing target for its pioneering product, AVERSA Fentanyl.

Sheridan expressed unwavering confidence in the current leadership team's ability to maintain the company's momentum, particularly in advancing AVERSA Fentanyl through the regulatory pipeline. The U.S. Food and Drug Administration (FDA) has recently granted a meeting request for AVERSA Fentanyl, marking a pivotal step forward for what is anticipated to be the first abuse-deterrent opioid patch on the market. Designed to combat misuse and accidental exposure, AVERSA Fentanyl holds the potential to generate peak U.S. sales between $80 million and $200 million. The technology behind AVERSA is protected by patents in 46 countries, with strategic plans underway to expand its availability to major global medical markets.

This leadership transition underscores Nutriband's commitment to both its corporate objectives and the broader societal impact of its innovations. The development of AVERSA Fentanyl represents a critical advancement in addressing the opioid crisis by introducing a safer alternative to traditional opioid patches. For more details on Nutriband's announcement, visit https://ibn.fm/YstUq. Further updates and news relating to Nutriband Inc. can be found in the company's newsroom at https://ibn.fm/NTRB.